Nivo-Cabo Combo Joins Advanced RCC Treatment Ranks Nivo-Cabo Combo Joins Advanced RCC Treatment Ranks
The PD-1 inhibitor/TKI combination is the latest to show superior survival in comparison with sunitinib as first-line therapy for patients with metastatic renal cell carcinoma (RCC).Medscape Medical News (Source: Medscape Urology Headlines)
Source: Medscape Urology Headlines - September 21, 2020 Category: Urology & Nephrology Tags: Hematology-Oncology News Source Type: news

New first-line treatment option for metastatic kidney cancer
(European Society for Medical Oncology) The results of the phase 3 CheckMate 9ER trial have provided a new first-line treatment option for patients with metastatic kidney cancer. The late breaking results are presented at ESMO 2020. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - September 19, 2020 Category: International Medicine & Public Health Source Type: news

Timing of Radiation Plus Immunotherapy Could Be Key to Antitumor Response in Kidney Cancer Timing of Radiation Plus Immunotherapy Could Be Key to Antitumor Response in Kidney Cancer
Appropriate timing of radiation and immunotherapy likely will improve the antitumor response in kidney cancer, a high-throughput analysis suggests.Reuters Health Information (Source: Medscape Pathology Headlines)
Source: Medscape Pathology Headlines - September 16, 2020 Category: Pathology Tags: Hematology-Oncology News Source Type: news

Novel discovery challenges a current kidney cancer paradigm
(Huntsman Cancer Institute) Newly published research has reversed our understanding of an aspect of kidney tumor growth. Researchers at Huntsman Cancer Institute at the University of Utah discovered that two key proteins have opposite roles than what was previously believed. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - September 11, 2020 Category: International Medicine & Public Health Source Type: news

'Deep dive' into biology of kidney tumors identifies markers of response to immunotherapy
(Memorial Sloan Kettering Cancer Center) An international team of investigators led by Memorial Sloan Kettering's Robert Motzer has identified biological attributes of kidney cancer tumors that correlate with better responses to immunotherapies and targeted therapies. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - September 7, 2020 Category: Cancer & Oncology Source Type: news

Kidney cancer symptoms: The warning sign on your testicles
KIDNEY cancer, also called renal cancer, is one of the most common types of cancer in the UK. The symptoms associated with kidney cancer can be vague and attributed to less serious conditions. One sign can be spotted on your testicles. (Source: Daily Express - Health)
Source: Daily Express - Health - August 20, 2020 Category: Consumer Health News Source Type: news

Researchers find link between gut microbiome and cancer treatment outcomes
(City of Hope) City of Hope and TGen have found that greater gut microbial diversity in patients with metastatic kidney cancer is associated with better treatment outcomes on FDA-approved immunotherapy regimens. A potential takeaway: Oncologists might encourage patients to eat a high-fiber diet, including fruits and vegetables high in fructo-oligosaccharides such as bananas, dried fruit, onions, leeks, garlic, asparagus and artichokes, as well as grains with resistant starches such as barley or uncooked potato starch. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - August 19, 2020 Category: International Medicine & Public Health Source Type: news

New 'two-pronged attack' drug treatment is giving kidney cancer patients longer and healthier lives
The combination of axitnib and avelumab is now available on the NHS in England, after health regulator the National Institute for Health and Care Excellence gave the green light last month. (Source: the Mail online | Health)
Source: the Mail online | Health - August 15, 2020 Category: Consumer Health News Source Type: news

Diabetes Linked to Increased Kidney Cancer Risk, But Only in Slim Diabetes Linked to Increased Kidney Cancer Risk, But Only in Slim
Postmenopausal women with BMIs under 30 are paradoxically more likely to develop kidney cancer than the women of the same age with higher BMIs and larger waists.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - August 13, 2020 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news

City of Hope, TGen looking to create personalized roadmaps for treatment of kidney cancer
(City of Hope) Experts at City of Hope and the Translational Genomics Research Institute (TGen) are using one of the world's most comprehensive genomic analysis tools to map out personalized treatment plans for metastatic kidney cancer patients. " The hope is to one day identify patients who will benefit from immunotherapy and those who will not. Eventually we may be able to distinguish which patient is better suited for other treatments, like targeted therapy, " said Sumanta Pal, M.D. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - July 22, 2020 Category: International Medicine & Public Health Source Type: news

ECR 2020: Radiologists, data scientists needed for AI
Greater involvement by radiologists and more help from data scientists are...Read more on AuntMinnie.comRelated Reading: ECR 2020: COVID-19 greatest health threat since Spanish flu SNMMI 2020: AI can aid in diagnosis of Parkinson's disease Are U.S. medical students avoiding radiology due to AI? AI could help radiologists better detect kidney cancer Coronavirus fears prompt rescheduling of ECR 2020 to July (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - July 17, 2020 Category: Radiology Source Type: news

Study Supports Changing Classification of Renal Cell Carcinoma Study Supports Changing Classification of Renal Cell Carcinoma
The definition of stage 4 renal cell carcinoma should be expanded to include lymph node-positive stage 3 disease, according to a new study.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - July 7, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Certain pesticides linked to kidney cancer in agricultural workers
New findings from the Agricultural Health Study suggest exposure to certain pesticides may increase risk of renal cell carcinoma. (read more) (Source: Environmental Factor - NIEHS Newsletter)
Source: Environmental Factor - NIEHS Newsletter - July 6, 2020 Category: Environmental Health Source Type: news

AI could help radiologists better detect kidney cancer
Artificial intelligence (AI) used with CT data could help abdominal radiologists...Read more on AuntMinnie.comRelated Reading: AI algorithm can help in incidental detection of PE SIIM 2020: COVID-19 could accelerate nonrad POCUS use SIIM 2020: The future is now for 3D imaging SIIM 2020: How to create robust radiology AI algorithms SIIM 2020: Human element shouldn't be neglected with AI (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - July 6, 2020 Category: Radiology Source Type: news

Liquid Biopsy Promising in Spotting Kidney Cancer Liquid Biopsy Promising in Spotting Kidney Cancer
An assay employing plasma and urine cell-free DNA methylomes is capable of classifying patients across all stages of renal-cell carcinoma, according to preliminary studies.Reuters Health Information (Source: Medscape Pathology Headlines)
Source: Medscape Pathology Headlines - July 2, 2020 Category: Pathology Tags: Hematology-Oncology News Source Type: news

Biomarker test highly accurate in detecting early kidney cancer
(Dana-Farber Cancer Institute) A novel liquid biopsy method can detect kidney cancers with high accuracy, including small, localized tumors which are often curable but for which no early detection method exists, say scientists from Dana-Farber Cancer Institute. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 22, 2020 Category: Cancer & Oncology Source Type: news

Good Survival Rates After Percutaneous Cryoablation for Early Renal Cell Carcinoma Good Survival Rates After Percutaneous Cryoablation for Early Renal Cell Carcinoma
Percutaneous cryoablation yields survival rates at least as good as those with nephrectomy in patients with stage 1 renal cell carcinoma, according to a prospective observational study.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 11, 2020 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Oncotarget: Hyperprogression to immune blockade followed by a response with cabozantinib
(Impact Journals LLC) Volume 11, Issue 22 of @Oncotarget reported that more and more patients receive first-line treatment with immunotherapy combinations and not all patients respond in metastatic renal cell carcinoma. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 10, 2020 Category: Cancer & Oncology Source Type: news

Percutaneous Cryoablation Treats Early-Stage Kidney Cancer
TUESDAY, June 9, 2020 -- Percutaneous cryoablation (PCA) for stage I renal cell carcinoma (RCC) results in good outcomes, with a 10-year disease-specific survival of 94 percent, according to a study published online June 9 in Radiology. John... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - June 9, 2020 Category: Pharmaceuticals Source Type: news

Cryoablation comparable to surgery for kidney cancer
Percutaneous cryoablation is comparable to surgery for treating kidney cancer,...Read more on AuntMinnie.comRelated Reading: 3D VR models improve kidney-sparing surgery outcomes How can 3D printing improve kidney cancer surgery? AR, 3D printing aid presurgical planning for kidney cancer Personalized treatment fights early-stage kidney cancer Do more CT scans lead to more kidney surgeries? (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - June 9, 2020 Category: Radiology Source Type: news

Freezing Kidney Tumors Offers Similar Survival Rate, Fewer Complications
Cryoablation offers patients with early-stage kidney cancer comparable results to surgery. (Source: Diagnostic Imaging)
Source: Diagnostic Imaging - June 9, 2020 Category: Radiology Authors: Whitney J. Palmer Tags: CT Kidney Cancer Source Type: news

Cryoablation comparable to surgery for treating early-stage kidney cancer
(Radiological Society of North America) A minimally invasive procedure that destroys cancer cells by freezing them is as effective as surgery for treating early-stage kidney cancer, offering similar 10-year survival rates with a lower rate of complications, according to a new study. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 9, 2020 Category: Cancer & Oncology Source Type: news

Elizabeth Plimack, MD, MS, Discusses Subsequent Therapy in Advanced RCC
Elizabeth Plimack, MD, MS, discussed the role of subsequent immunotherapy when analyzing the primary endpoint of overall survival for axitinib and pembrolizumab over sunitinib in patients with advanced renal cell carcinoma evaluated in the updated analysis of KEYNOTE-426. (Source: CancerNetwork)
Source: CancerNetwork - June 9, 2020 Category: Cancer & Oncology Authors: Elizabeth R. Plimack, MD, MS Source Type: news

UT Health San Antonio study shows Nox4 protein may predict untreatable kidney cancer
(University of Texas Health Science Center at San Antonio) University of Texas Health Science Center at San Antonio researchers confirmed the role of a certain protein, Nox4, in the development of high-grade kidney cancer. The researchers also showed that a higher level of the protein can be used as a marker to predict in humans which tumors will develop treatment resistance and progress more rapidly. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 3, 2020 Category: International Medicine & Public Health Source Type: news

Health Experts Criticize EPA ’s Asbestos Draft Risk Evaluation
Doctors, scientists and occupational health experts from across the country are openly criticizing the U.S. Environmental Protection Agency’s recent asbestos draft risk evaluation. At a virtual press conference arranged by the Asbestos Disease Awareness Organization last week, speakers labeled the asbestos evaluation inadequate and in need of serious revision. The year-long evaluation was required as part of the Frank R. Lautenberg Chemical Safety for the 21st Century Act, which was passed in 2016. It amended the original Toxic Substances Control Act, the country’s primary chemicals management law. “I am...
Source: Asbestos and Mesothelioma News - June 2, 2020 Category: Environmental Health Authors: Fran Mannino Source Type: news

Eric Jonasch, MD, on Next Steps in MK-6482 in VHL Disease –Associated RCC
The MD Anderson Cancer Center expert discussed next steps for those with von Hippel-Lindau disease –associated renal cell carcinoma being treated with the HIF-2a Inhibitor. (Source: CancerNetwork)
Source: CancerNetwork - June 2, 2020 Category: Cancer & Oncology Authors: Eric Jonasch, MD Source Type: news

Eric Jonasch, MD, Discusses Use of MK-6482 in VHL Disease –Associated Kidney Cancer
The HIF-2a Inhibitor, MK-6482, induced clinical responses among patients with von Hippel-Lindau disease –associated renal cell carcinoma. (Source: CancerNetwork)
Source: CancerNetwork - May 30, 2020 Category: Cancer & Oncology Authors: Eric Jonasch, MD Source Type: news

Study reveals factors influencing outcomes in kidney cancer treated with immunotherapy
(Dana-Farber Cancer Institute) By analyzing tumors from patients treated with immunotherapy for advanced kidney cancer in three clinical trials, Dana-Farber Cancer Institute scientists have identified several features of the tumors that influence their response to immune checkpoint inhibitor drugs. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 29, 2020 Category: Cancer & Oncology Source Type: news

Final Data Analysis Supports Tivozanib as Superior Treatment for Patients With RCC
When compared with sorafenib, tivozanib showed improved progression-free survival, and a more manageable safety profile for patients with relapsed or refractory metastatic renal cell carcinoma. (Source: CancerNetwork)
Source: CancerNetwork - May 29, 2020 Category: Cancer & Oncology Authors: Kevin Wright Source Type: news

Savolitinib Induces Encouraging Efficacy, Safety in MET-Driven Papillary Renal Cell Carcinoma
A phase III study presented the 2020 ASCO Virtual Scientific Program showed encouraging efficacy data suggesting savolitinib could be used to treat patients with MET-driven papillary renal cell carcinoma. (Source: CancerNetwork)
Source: CancerNetwork - May 29, 2020 Category: Cancer & Oncology Authors: Matthew Fowler Source Type: news

Novel targeted drug induced positive response for VHL-associated kidney cancer
(University of Texas M. D. Anderson Cancer Center) In an international trial led by researchers at The University of Texas MD Anderson Cancer Center, treatment with MK-6482, the small molecule inhibitor of hypoxia-inducible factor (HIF)-2a was well tolerated and resulted in clinical responses for patients with von Hippel-Lindau disease (VHL)-associated renal cell carcinoma (RCC). (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 28, 2020 Category: Cancer & Oncology Source Type: news

Tivozanib Induces Durable Response Among Patients with Advanced Renal Cell Carcinoma
The VEGF TKI induced durable responses and favorable tolerability in patients with relapsed/refractory RCC. (Source: CancerNetwork)
Source: CancerNetwork - May 20, 2020 Category: Cancer & Oncology Authors: Kristie L. Kahl Source Type: news

Upstate professor lands federal grant to continue kidney cancer research
Funding will continue a decade-long research project into kidney cancer biology. (Source: SUNY Upstate Medical)
Source: SUNY Upstate Medical - May 13, 2020 Category: Universities & Medical Training Tags: News Source Type: news

Mesothelioma Drug Combination Continues to Show Promise
Pharmaceutical giant Bristol Myers Squibb continues to tout its immunotherapy combination of Opdivo and Yervoy for first-line treatment of patients with pleural mesothelioma cancer. Bristol Myers Squibb recently announced that overall survival “significantly improved” when the combination was measured against standard chemotherapy in a randomized, phase III clinical trial of previously untreated mesothelioma patients. Its announcement was based on a pre-specific interim analysis conducted by the Data Monitoring Committee, a clinical study organization independent of Bristol Myers Squibb. The study is being cond...
Source: Asbestos and Mesothelioma News - May 4, 2020 Category: Environmental Health Authors: Fran Mannino Source Type: news

Kidney Cancer Destination Could Guide Treatment Decisions Moving Forward
A recent study examined pancreatic metastases to understand why patients with this particular kidney cancer have better prognoses, and sought to characterize the clinical behavior, therapeutic implications, and underlying biology of this type of cancer. (Source: CancerNetwork)
Source: CancerNetwork - April 27, 2020 Category: Cancer & Oncology Authors: Matthew Fowler Source Type: news

Phase III CheckMate-9ER Trial Meets Primary Endpoint in Advanced RCC Trial
The trial evaluated nivolumab in combination with cabozantinib compared to sunitinib in previously untreated advanced or metastatic renal cell carcinoma, meeting its primary endpoint of progression-free survival at final analysis. (Source: CancerNetwork)
Source: CancerNetwork - April 21, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news

How this East Bay biotech pushed past the 'negativity' with a big boost to its kidney cancer drug
The questions had been circling Exelixis Inc. for the past 18 months: Was its signature drug — the one key to the company's comeback, growth and a chunk of its future plans — too late to the game of pairing up with a cancer immunotherapy to treat kidney cancer? Was the market too competitive? Would the combo of Cabometyx and Bristol-Myers Squibb Co.'s just not be enough? The answers c ame this morning from the Alameda-based company (NASDAQ: EXEL) and Bristol-Myers Squibb (NYSE: BMY): No, Exelixis… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - April 21, 2020 Category: Pharmaceuticals Authors: Ron Leuty Source Type: news

How this East Bay biotech pushed past the 'negativity' with a big boost to its kidney cancer drug
The questions had been circling Exelixis Inc. for the past 18 months: Was its signature drug — the one key to the company's comeback, growth and a chunk of its future plans — too late to the game of pairing up with a cancer immunotherapy to treat kidney cancer? Was the market too competitive? Would the combo of Cabometyx and Bristol-Myers Squibb Co.'s just not be enough? The answers c ame this morning from the Alameda-based company (NASDAQ: EXEL) and Bristol-Myers Squibb (NYSE: BMY): No, Exelixis… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - April 21, 2020 Category: Biotechnology Authors: Ron Leuty Source Type: news

US researchers collaborate with scientist quarantined in China during COVID-19 outbreak
(Regenstrief Institute) Despite significant obstacles presented by COVID-19, Regenstrief Institute Affiliated Scientist Jie Zhang, PhD, Regenstrief Institute Research Scientist Kun Huang, PhD, both Indiana University School of Medicine faculty members, and Jun Cheng, PhD of Shenzhen University conducted a study applying machine learning and image analysis to distinguish a rare subtype of kidney cancer (tRCC ) while Dr. Cheng was quarantined in Wuhan. The study is published in the April 14, 2020 issue of Nature Communications. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 20, 2020 Category: Cancer & Oncology Source Type: news

Renal Cell Cancer
(Source: eMedicineHealth.com)
Source: eMedicineHealth.com - April 15, 2020 Category: General Medicine Source Type: news

AVEO Oncology Announces Submission of New Drug Application to U.S. FDA for Tivozanib in Patients with Relapsed or Refractory Renal Cell Carcinoma
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar. 31, 2020-- AVEO Oncology (NASDAQ: AVEO) today announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for tivozanib, the Company’s... (Source: Drugs.com - New Drug Applications)
Source: Drugs.com - New Drug Applications - March 31, 2020 Category: Drugs & Pharmacology Source Type: news

AR, 3D printing set to improve cranial surgery outcomes
Researchers from Brazil have developed a way to visualize and interact with...Read more on AuntMinnie.comRelated Reading: AR equipped to 'transform' image-guided interventions AR, 3D printing make waves in cardiac care AR offers 3D image guidance for interventional procedures AR, 3D printing enhance planning for complex heart surgery AR, 3D printing aid presurgical planning for kidney cancer (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - March 27, 2020 Category: Radiology Source Type: news

Acute Kidney Injury Seems to Promote Renal Cell Carcinoma
AKI promotes the development of papillary renal cell carcinoma from single progenitors (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - March 26, 2020 Category: Cancer & Oncology Tags: Nephrology, Oncology, Pathology, Journal, Source Type: news

Acute Kidney Injury Seems to Promote Renal Cell Carcinoma
THURSDAY, March 26, 2020 -- Acute kidney injury (AKI) seems to promote the development of papillary renal cell carcinoma (pRCC) from single progenitors, according to a study published in the March 25 issue of Science Translational Medicine. Anna... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - March 26, 2020 Category: Pharmaceuticals Source Type: news

Adjuvant Chemo Halves Recurrence Risk in Rare Kidney Cancer Adjuvant Chemo Halves Recurrence Risk in Rare Kidney Cancer
The risk of recurrence in a rare form of urothelial carcinoma is halved by adding chemotherapy to surgery, the results of a UK study reveal, although many questions remained to be answered.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - March 11, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Chemotherapy after surgery halves risk of rare kidney cancer coming back
(Institute of Cancer Research) Chemotherapy halves the risk of a rare form of kidney cancer coming back after surgery, the largest ever trial conducted in the disease worldwide has found.Patients given chemotherapy within three months of surgery saw the risk of their cancer coming back or spreading reduced and were much more likely to live cancer free for three years or more. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - March 5, 2020 Category: Cancer & Oncology Source Type: news

Findings Establish PT2385 as a Highly Specific HIF-2 Inhibitor for Patients with Clear Cell RCC
The findings reported in this study demonstrated a core dependency on HIF-2 in metastatic clear cell renal cell carcinoma and established PT2385 as a highly specific HIF-2 inhibitor. (Source: CancerNetwork)
Source: CancerNetwork - February 27, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news

3D light scanner supplements CT for bedside procedures
Researchers from Tennessee have developed a navigation technique that employs...Read more on AuntMinnie.comRelated Reading: 3D micro-CT primed to revamp breast cancer imaging 3D printing may improve safety of upper GI surgery 3D-printed head customizes neurosurgery simulation How can 3D printing improve kidney cancer surgery? Portable gaming sensor enables 3D scans of elephantiasis (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - February 24, 2020 Category: Radiology Source Type: news

Scientists receive CPRIT grants for lung, kidney cancer research
(University of Texas at Dallas) The Cancer Prevention and Research Institute of Texas (CPRIT) has awarded new grants totaling $1.8 million to two University of Texas at Dallas scientists for their research related to lung and kidney cancers. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - February 21, 2020 Category: Cancer & Oncology Source Type: news

RSNA, ACR draft dictionary for 3D printing registry
The RSNA and American College of Radiology (ACR) released a data dictionary...Read more on AuntMinnie.comRelated Reading: 3 ways to advance 3D printing in radiology AR, 3D printing make waves in cardiac care 3D printing helps unravel rare cardiac anomalies 3D printing may improve safety of upper GI surgery How can 3D printing improve kidney cancer surgery? (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - February 20, 2020 Category: Radiology Source Type: news